Skip to main content


Showing posts from June, 2011

Almost 16,000 COVID-19 patients get hydroxychloroquine and here's what happened

In a new study from Brigham and Women’s hospital, nearly 16,000 patient outcomes were analyzed that were diagnosed with COVID-19 and received the drug hydroxychloroquine.
Instead of improving, patients were four times more likely to experience dangerous heart irregularity, compared to those not teated with the antimalarial drug.
Patients in the study that were given hydroxychloroquine were also more likely to die.
The study is recently published in the medical journal The Lancet  and is the most recent to address a hot topic about whether the medication, which is also prescribed to treat autoimmune disorders, should be  used to treat COVID-19.
Mandeep R. Mehra, a corresponding study author and executive director of the Brigham’s Center for Advanced Heart  Disease said the drug, or any regimen including a chloroquine,  did not help “no matter which way you examine the data.”
Patients from six continents included 
The researchers looked at data from 671 hospitals that included six continents …

Potential E. coli treatment developed 10 years ago

E. coli treatment ignored, but developed a decade ago

Scientists from the University of Adelaide say they developed a possible treatment that could stop deadly E. coli in its tracks a decade ago that never went to clinical trial because of lack of interest from commercial sectors.
The scientists produced a probiotic that binds to E. coli and was shown to protect mice from the harmful effects of toxins produced by E. coli that is claiming lives in Europe.
E. coli can shut down the kidneys and attack blood vessels, leading to severe illness and death. Researchers Dr Adrienne Paton, Associate Professor Renato Morona and Professor James Paton infected mice with virulent strains of E. coli in 2000.
The researchers published their findings that the mice were completely protected from fatal doses of toxins that produce gastrointestinal disease in journal Nature Medicine, but no further studies were developed.
The researchers say if the probiotic had gotten the attention of investors, and proved …